Novo Nordisk has filed suit against telehealth provider Hims & Hers, alleging that the startup’s planned oral version of Wegovy infringes on formulation patents originally granted for Novo’s weekly injectable obesity drug. The complaint highlights Hims & Hers’s recent change of strategy—abandoning then reinstating its pill offering—and seeks to block any unauthorized use or sale of the contested oral formulation. By enforcing its intellectual property rights, Novo aims to curb emerging competition in the fast-growing GLP-1 obesity treatment market and safeguard billions in potential future sales.